Skip to main content
. Author manuscript; available in PMC: 2010 Feb 1.
Published in final edited form as: Clin Cancer Res. 2009 Feb 1;15(3):1024–1031. doi: 10.1158/1078-0432.CCR-08-1143

Figure 4. Urinary cystatin B level is predictive of time to TCC disease recurrence and disease grade/stage progression.

Figure 4

Kaplan Meier analysis was used to estimate (A) disease recurrence-free survival, and (B) grade/stage progression-free survival, for patients with high (cutoff ≥0.54) or low urinary cystatin B levels. High cystatin B was significantly associated with earlier disease recurrence (p=0.0047) and stage or grade progression (p=0.0007, Log Rank test). Plus signs along plots indicate censored data.